CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02808650
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.087456+00:00
Published At: 2023-12-20T00:00:00+00:00
Record Updated At: 2023-12-20
Results Posted At: 2023-12-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-20"
protocolSection.identificationModule.nctId: "NCT02808650"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-20"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.